按品牌選擇
|
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評論] [本類其他產(chǎn)品] [本類其他供應(yīng)商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷售商： 北京啟維益成科技有限公司 | 查看該公司所有產(chǎn)品 >> |
| Catalogue Number | CYT-281 |
| Synonyms | Fibroblast growth factor 21, FGF-21. |
| Introduction | The FGFs are a family of more than 20 small (~17–26 kDa) secreted peptides. The initial characterization of these proteins focused on their ability to stimulate fibroblast proliferation. This mitogenic activity was mediated through FGF receptors (FGFRs) 1, 2, or 3. A fourth closely related tyrosine kinase receptor (FGFR4) was able to bind the FGFs but did not lead to a mitogenic response. FGFs modulate cellular activity via at least 5 distinct subfamilies of high-affinity FGF receptors (FGFRs): FGFR-1, -2, -3, and -4, all with intrinsic tyrosine kinase activity and, except for FGFR-4, multiple splice isoforms, and FGFR-5, which lacks an intracellular kinase domain. There is growing evidence that FGFRs can be important for regulation of glucose and lipid homeostasis. The overexpression of a dominant negative form of FGFR-1 in ? cells leads to diabetes in mice, which thus implies that proper FGF signaling is required for normal ? cell function and glycemia maintenance. FGFR-2 appears to be a key molecule during pancreatic development. Moreover, FGFR-4 has been implicated in cholesterol metabolism and bile acid synthesis. FGF-19, has been shown to cause resistance to diet-induced obesity and insulin desensitization and to improve insulin, glucose, and lipid profiles in diabetic rodents. Since these effects, at least in part, are mediated through the observed changes in metabolic rates, FGF-19 can be considered as a regulator of energy expenditure. FGF-21 is preferentially expressed in liver, but an exact knowledge of FGF-21 bioactivity and its mode of action have been lacking to date. FGF-21 is a potent activator of glucose uptake on adipocytes, protects animals from diet-induced obesity when overexpressed in transgenic mice, and lowers blood glucose and triglyceride levels when therapeutically administered to diabetic rodents. |
| Description | Fibroblast Growth Factor -21 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 202 amino acids (29-209) and having a molecular mass of 21.6 kDa. The FGF-21 is fused to 20 amino acid His Tga at N-terminus and purified by proprietary chromatographic techniques. |
| Source | Escherichia Coli. |
| Physical Appearance | Sterile Filtered colorless clear solution. |
| Formulation | The FGF-21 His tag protein solution in 20mM Tris-HCL buffer pH-8 and 10% glycerol. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles. |
| Purity | Greater than 90.0% as determined by SDS-PAGE. |
| Amino acid sequence | MGSSHHHHHH SSGLVPRGSH MHPIPDSSPL LQFGGQVRQR YLYTDDAQQT EAHLEIREDG TVGGAADQSP ESLLQLKALK PGVIQILGVKTSRFLCQRPD GALYGSLHFD PEACSFRELL LEDGYNVYQS EAHGLPLHLP GNKSPHRDPA PRGPARFLPL PGLPPAPPEP PGILAPQPPD VGSSDPLSMV GPSQGRSPSY AS. |
| Biological Activity | Measured in a cell proliferation assay using NIH-3T3 cells. The ED50 for this effect is < 12ng/ml, which corresponds to > 83,000 units/ml. |
| Usage | ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs,agricultural or pesticidal products, food additives or household chemicals. |
- 大鼠肺泡巨噬細(xì)胞(NR8383)培養(yǎng)要點
- 干細(xì)胞誘導(dǎo)生成類器官的工藝要點淺析
- 細(xì)胞復(fù)蘇的原理、實驗步驟及注意事項
- 10個獲批干細(xì)胞新藥IND及細(xì)胞療法應(yīng)用案例分享
- 寵物干細(xì)胞行業(yè)技術(shù)服務(wù)體系及在治療中的應(yīng)用
- 《人臍帶間充質(zhì)干細(xì)胞治療膝骨性關(guān)節(jié)炎臨床應(yīng)用指南》內(nèi)容及適用范圍
- 免疫B細(xì)胞的分類、活化機制、主要功能及在疾病治療中的應(yīng)用
- 自然殺傷細(xì)胞（NK細(xì)胞）的功能及培養(yǎng)流程
Copyright(C) 1998-2025 生物器材網(wǎng) 電話：021-64166852;13621656896 E-mail：info@bio-equip.com